Abstract

The human epidermal growth factor receptor 2 gene ERBB2 (HER2) is amplified in many cancer types. Overexpression of ERBB2 has been used successfully as a therapeutic target in breast and gastric cancers with a variety of anti-ERBB2 agents. In contrast, the role of ERBB2 in colorectal cancer is evolving. Molecular characterization of colorectal cancer has identified ERBB2 amplification as a potential therapeutic target, and activation of ERBB2 signaling causes resistance to anti–epidermal growth factor receptor (EGFR) therapy in a subset of patients with metastatic colorectal cancer.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call